Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Health Sciences Group, Inc. (HESG)
Newport Beach, CA, US
Operating through its various subsidiaries, Health Sciences Group Inc. (HESG) specializes in supplying a range of ingredients and finished products for the nutritional supplement and functional food and beverage sectors across the United States. Key among its offerings is Shugr, an innovative, calorie-free sugar alternative meticulously formulated to replicate the taste and baking properties of traditional cane sugar. Another notable product is the Sequesterol Advance Cardio Formula, a proprietary blend featuring clinically validated ingredients designed to support robust cardiovascular well-being and maintain optimal blood circulation. The company's portfolio further includes Aplevia, an antioxidant extracted from apple peels, and Edible Sponges, an open-cell hydrocolloid product. Distribution channels for these products are diverse, encompassing major retail chains — such as mass merchandisers, pharmacies, grocery stores, and discount outlets — alongside sales to healthcare professionals, practitioners, and various other media platforms. Tracing its origins to 1996 as Centurion Properties Development Corporation, the company underwent a name change to iGoHealthy.com in 2000, before adopting its current designation, Health Sciences Group, Inc., in 2001. Its corporate headquarters are situated in Newport Beach, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +9,900.00% | +900.00% | +900.00% | +900.00% | +900.00% | +0.00% | -75.00% | +0.00% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+496.0% ★ Q3'06: -74.5% (vs Q3'05)
-
EPS growth Biotechnology: +29.7%+88.4% ★ Q3'06: +66.7% (vs Q3'05)
-
FCF margin FCF growth · Biotechnology: +16.2%+14.4% Q3'06: -948.6% (vs Q3'05)
-
EBIT margin Biotechnology: +0.0%-15.2% Q3'06: -18,430.1% (vs Q3'05)
-
ROIC Biotechnology: -16.1%-6.0% ★ Q3'06: +84.8% (vs Q3'05)
-
Share dilution Biotechnology: -3.4%-92.4% ★ Q3'06: +60.7% (vs Q3'05)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-7.16× Q3'06: -0.20× (vs Q3'05)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fred Aserati | Vice President of Business Development | — | — |
| Raymond C. Signore | Director of Sales & Marketing | — | male |
| Thomas Gaffney | Chief Executive Officer and President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HESG
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
